Johnson & Johnson
JNJ
$228.92
+0.97%
Johnson & Johnson is the world's largest and most diverse healthcare firm, operating through two core divisions: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). The company is a dominant market leader with a century-long reputation for stability, having recently completed a strategic transformation by divesting its consumer health business (Kenvue) to focus purely on higher-margin, innovation-driven healthcare segments. The current investor narrative centers on the company's post-divestiture identity as a pure-play healthcare giant, navigating the near-term headwind from declining sales of its blockbuster drug Stelara while leveraging its robust pipeline in immunology, oncology, and neurology to drive future growth, against a backdrop of evolving regulatory and pricing dynamics in the pharmaceutical industry.…
JNJ
Johnson & Johnson
$228.92
Related headlines
Investment Opinion: Should I buy JNJ Today?
Rating & Thesis: Hold. JNJ is a high-quality, defensive cornerstone for a portfolio, but its near-term growth headwinds and technical weakness suggest it is fairly valued at current levels, warranting patience for a better entry point rather than immediate accumulation. This aligns with the analyst community's stable but not aggressively bullish consensus, which implies steady, single-digit upside based on earnings estimates.
Supporting Evidence: The hold thesis is supported by four key data points: 1) Valuation is reasonable but not cheap, with a forward P/E of 17.84x in line with large-cap pharma peers, offering limited multiple expansion potential. 2) Revenue growth, while positive at 9.08% YoY, is decelerating and faces a known headwind (Stelara). 3) Profitability is a strength, with net margins above 20% and stellar ROE of 32.87%, but this is already reflected in the price. 4) The stock's low beta of 0.263 confirms its defensive role, but it has recently underperformed the market significantly (-15.3% relative strength over 3 months), indicating lack of near-term catalyst.
Risks & Conditions: The two biggest risks to this hold rating are an acceleration of Stelara's decline worsening growth deceleration, and a failure of pipeline catalysts to gain material traction. This Hold would upgrade to a Buy if the stock's forward P/E compressed below 16x (offering a clearer margin of safety) or if quarterly revenue growth re-accelerates above 12% YoY, signaling successful pipeline offset. It would downgrade to Sell if revenue growth turns negative or if technical support at $221 fails decisively. The valuation verdict is that JNJ is fairly valued relative to its own history and peer set, trading at a justified premium for its quality but not at a discount that demands immediate action.
Sign up to view all
JNJ 12-Month Price Forecast
The 12-month outlook for JNJ is one of transition and range-bound consolidation. The company's immense financial strength and low volatility provide a solid floor, but near-term growth is in a precarious phase as it pivots away from legacy blockbusters. The base case (60% probability) of steady, single-digit returns is most likely, driven by earnings growth and dividend yield. The bull case requires flawless pipeline execution—a possible but not probable near-term outcome. The stance is neutral because the stock lacks a clear near-term catalyst for outperformance, and its recent technical breakdown suggests it needs time to rebuild momentum. We would upgrade to bullish on evidence of re-accelerating organic growth or a deeper valuation pullback; a downgrade to bearish would follow a breakdown of the $220 support level.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Johnson & Johnson's 12-month outlook, with a consensus price target around $297.60 and implied upside of +30.0% versus the current price.
Average Target
$297.60
15 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
15
covering this stock
Price Range
$183 - $298
Analyst target range
Analyst coverage for Johnson & Johnson is extensive and robust, with 15 analysts providing estimates, reflecting its status as a large-cap, blue-chip institution. The consensus sentiment leans bullish, as evidenced by recent institutional actions including upgrades to 'Overweight' by Morgan Stanley and maintained 'Buy' or 'Outperform' ratings from firms like RBC Capital, Citigroup, and HSBC. The average target price implied by earnings estimates is approximately $17.68 per share for EPS, though a specific consensus price target is not provided in the dataset; the implied upside must be calculated from future earnings expectations rather than a stated price. The target range for estimated EPS is from a low of $17.06 to a high of $18.06, representing a relatively tight spread of about 6%. This narrow range indicates strong analyst conviction in the company's earnings trajectory and a lower degree of uncertainty typical for a stable, predictable giant like JNJ. The high-end target likely assumes successful pipeline execution, market share gains, and stable margins, while the low-end may factor in greater-than-expected competitive or pricing pressures. The pattern of recent ratings shows a generally stable to positive bias, with no major downgrades, reinforcing the view of JNJ as a core, long-term holding in the healthcare sector.
Bulls vs Bears: JNJ Investment Factors
The evidence presents a classic tension between JNJ's formidable defensive strengths and its emerging growth challenges. The bull case is anchored in unparalleled financial fortitude: exceptional cash flow, pristine margins, low volatility, and analyst confidence in its earnings stability. The bear case highlights concerning momentum: a sharp technical correction, decelerating revenue growth amid a key drug's decline, and a valuation that demands flawless pipeline execution. Currently, the bearish near-term momentum and growth concerns hold slightly stronger evidence, as they directly challenge the stock's recent performance and forward narrative. The single most important tension in the investment debate is the race between JNJ's robust financial engine and its ability to deploy that capital to rapidly regenerate top-line growth through its pipeline, thereby justifying its premium valuation before Stelara's decline creates an earnings gap.
Bullish
- Exceptional Profitability & Cash Flow: JNJ's Q4 2025 net margin was 20.83% and trailing twelve-month free cash flow reached $19.70 billion. This robust financial engine funds a reliable dividend, share buybacks, and pipeline investment, underpinning its AAA credit rating and defensive appeal.
- Strong Post-Divestiture Margins: The company's strategic focus on high-margin healthcare segments is evident in a Q4 2025 gross margin of 86.37%. This elevated profitability, driven by the pure-play Innovative Medicine and MedTech mix, enhances returns on capital, as shown by a 32.87% ROE.
- Analyst Conviction & Stable Earnings Outlook: Coverage by 15 analysts shows a tight EPS estimate range of $17.06 to $18.06, a spread of only 6%. This high conviction, coupled with recent 'Overweight' and 'Buy' ratings from major firms, reflects confidence in JNJ's predictable earnings trajectory post-restructuring.
- Defensive Profile with Low Volatility: A beta of 0.263 means JNJ's stock is approximately 74% less volatile than the broader market. This characteristic, combined with its 51.53% one-year gain, makes it a resilient holding during market downturns, appealing to risk-averse investors.
Bearish
- Significant Near-Term Technical Weakness: The stock is down 5.01% over the past month and 6.88% over three months, sharply underperforming the SPY by over 10% and 15%, respectively. This divergence from the long-term uptrend signals a potential trend reversal or deep correction.
- Revenue Growth Deceleration & Stelara Headwind: While Q4 2025 revenue grew 9.08% YoY, this marks a sequential deceleration. Recent news highlights a 'steep sales decline' for blockbuster drug Stelara, creating a tangible near-term headwind that tempers top-line momentum for the core Innovative Medicine segment.
- Premium Valuation vs. Mature Growth Profile: A forward P/E of 17.84x and P/S of 5.35x command a premium for a company with single-digit revenue growth. If pipeline catalysts fail to materialize quickly to offset patent losses, this premium multiple is at risk of compression.
- Pipeline Dependency Amid Regulatory Uncertainty: Future growth hinges on successful pipeline execution in immunology, oncology, and neurology. This comes amid evolving regulatory and pricing dynamics, including the threat of punitive tariffs for companies without pricing deals, introducing execution and political risk.
JNJ Technical Analysis
The stock is in a sustained long-term uptrend, evidenced by a formidable 51.53% gain over the past year, but is currently experiencing a significant near-term correction. Trading at a current price of $226.71, it sits approximately 69% of the way up from its 52-week low of $149.04 towards its high of $251.71, indicating it has retreated meaningfully from recent peaks and is now in a middle-ground position that could represent either a consolidation zone or a pause before further decline. Recent momentum has turned sharply negative, with the stock down 5.01% over the past month and 6.88% over the past three months, a stark divergence from the powerful yearly uptrend that signals a potential trend reversal or a deep pullback within the broader bull market, exacerbated by its significant underperformance relative to the SPY over these periods. Key technical support is anchored at the 52-week low of $149.04, though more immediate support likely resides near recent lows around $221, while resistance is firmly established at the 52-week high of $251.71. A decisive breakout above $251.71 would signal a resumption of the primary uptrend, whereas a breakdown below the $221-$225 area could open the door for a deeper correction towards the $200 level. The stock exhibits low market-relative volatility with a beta of 0.263, meaning it is approximately 74% less volatile than the broader market, which historically makes it a defensive holding but does not preclude it from experiencing significant idiosyncratic moves based on company-specific news.
Beta
0.26
0.26x market volatility
Max Drawdown
-11.0%
Largest decline past year
52-Week Range
$149-$252
Price range past year
Annual Return
+51.3%
Cumulative gain past year
| Period | JNJ Return | S&P 500 |
|---|---|---|
| 1m | -2.2% | +4.0% |
| 3m | -5.9% | +8.2% |
| 6m | +13.0% | +11.5% |
| 1y | +51.3% | +24.3% |
| ytd | +10.4% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
JNJ Fundamental Analysis
Revenue growth remains positive but is showing signs of deceleration on a sequential basis; the most recent Q4 2025 revenue was $24.56 billion, representing a solid 9.08% year-over-year increase, yet this marks a slowdown from the stronger growth rates seen in prior quarters of 2025. The growth is bifurcated, with the Innovative Medicine segment contributing $15.76 billion and MedTech contributing $8.80 billion in the latest period, indicating the pharmaceutical division is the primary growth engine, though it faces looming patent expiries. The revenue trajectory suggests a company in transition, growing but facing near-term headwinds that are tempering investor enthusiasm for the top line. Profitability is robust, with the company generating a net income of $5.12 billion in Q4 2025, translating to a healthy net margin of 20.83%. Gross margins are exceptionally strong at 86.37% for the quarter, though this is elevated due to the high-margin pharmaceutical mix post-consumer divestiture; the trailing twelve-month gross margin is 72.78%. The margin profile indicates a highly profitable enterprise, but investors must monitor for potential compression as the product mix evolves and the company invests in its pipeline, with operating margins at 21.95% for the quarter demonstrating efficient cost management. The balance sheet and cash flow position are pillars of strength, supporting the company's AAA credit rating and reliable dividend. Free cash flow over the trailing twelve months is a substantial $19.70 billion, providing ample internal funding for dividends, share repurchases, and business development. The debt-to-equity ratio is a conservative 0.59, indicating a prudent capital structure with low financial risk. Furthermore, the company's return on equity is an impressive 32.87%, showcasing highly efficient use of shareholder capital, while the current ratio of 1.03, though modest, is sufficient for a company with such stable and predictable cash flows.
Quarterly Revenue
$24.6B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.86%
Latest Quarter
Free Cash Flow
$19.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is JNJ Overvalued?
Given the company's consistent profitability, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 18.81x, while the forward PE is slightly lower at 17.84x, indicating the market expects modest earnings growth. The narrow gap between trailing and forward multiples suggests consensus expectations are for steady, rather than explosive, near-term profit expansion, which is typical for a mature healthcare giant. Compared to the broader Drug Manufacturers industry, JNJ's valuation presents a mixed picture. Its trailing PE of 18.81x is generally in line with or at a modest premium to large-cap pharmaceutical peers, which often trade in the mid-to-high teens. The Price-to-Sales ratio of 5.35x and EV-to-Sales of 6.11x reflect the market's pricing of its high-margin, post-divestiture sales base. The premium, if any, is justified by its industry-leading scale, diversified healthcare portfolio, pristine balance sheet, and legendary dividend stability, which command a quality and safety premium among investors. Historically, JNJ's current trailing PE of 18.81x sits comfortably within its own multi-year range, which has seen periods both significantly higher and lower. It is notably below the elevated multiples seen during the peak of the pandemic and subsequent market volatility. This positioning suggests the stock is not excessively valued by its own historical standards, potentially offering a reasonable entry point for long-term investors seeking quality, provided the company's growth narrative remains intact post its major restructuring.
PE
18.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -1502x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: JNJ's primary financial risk is not solvency—its debt-to-equity of 0.59 and $19.7B in TTM FCF are rock-solid—but rather earnings volatility and growth sustainability. Revenue growth decelerated to 9.08% YoY in Q4 2025, and the company faces a significant, quantifiable headwind from the declining sales of its blockbuster drug Stelara. While net margins are healthy at 20.83%, they are susceptible to compression if the company must increase R&D (Q4 2025: $4.25B) or SG&A spending more aggressively to fuel the pipeline without corresponding revenue acceleration, potentially straining its high return on equity of 32.87%.
Market & Competitive Risks: The stock trades at a forward P/E of 17.84x, a premium valuation that embeds expectations for successful pipeline execution. The key market risk is multiple compression if growth fails to re-accelerate, especially as the stock has already gained 51.53% over the past year and is now correcting. Competitively, new drug approvals (like the recent oral psoriasis pill) are a double-edged sword, shaking up rivals like AbbVie but also inviting fierce competition in core therapeutic areas. Furthermore, the evolving regulatory landscape, highlighted by news of potential 100% tariffs on drugmakers without pricing deals, introduces a non-fundamental political risk that could disrupt sector valuations.
Worst-Case Scenario: The most damaging scenario involves a perfect storm: a faster-than-expected cliff in Stelara sales, consecutive pipeline setbacks in key late-stage trials, and a broader market downturn that removes the safety premium from defensive stocks. This could trigger analyst downgrades from the current bullish consensus and a re-rating towards the lower end of its historical P/E range. Quantifying the downside, a break below key support near $221 could see the stock retreat towards its 52-week low of $149.04, representing a potential loss of approximately -34% from the current price of $226.71. A more immediate bear-case target in a deteriorating scenario would be the $200 level, a -12% decline.
FAQ
The key risks are, in order of severity: 1) Product Concentration & Pipeline Risk: The steep decline of blockbuster drug Stelara creates a near-term earnings headwind, and future growth is dependent on unproven pipeline candidates. 2) Valuation Compression: Trading at a forward P/E premium (17.84x), the stock is vulnerable if growth disappoints. 3) Regulatory & Political Risk: Evolving drug pricing policies and potential tariffs, as highlighted in recent news, create sector-wide uncertainty. 4) Execution Risk in Transition: The company must prove it can deliver consistent growth as a pure-play healthcare firm post the Kenvue spin-off, a narrative still in flux.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $225 and $245, driven by meeting consensus EPS estimates of ~$17.68 and stable valuation multiples. The Bull Case (25% probability) targets a breakout above the 52-week high of $251.71 to $265, requiring successful pipeline execution and multiple expansion. The Bear Case (15% probability) envisions a drop to $200-$221 if growth headwinds intensify and support breaks. The most likely outcome is the Base Case of range-bound consolidation with a slight upward bias, as the company navigates its near-term challenges.
JNJ stock is fairly valued. Its trailing P/E of 18.81x and forward P/E of 17.84x are in line with, or at a modest premium to, large-cap pharmaceutical peers, justified by its industry-leading scale, AAA balance sheet, and high profitability (32.87% ROE). The Price-to-Sales ratio of 5.35x reflects its high-margin sales base post-consumer divestiture. Historically, the current P/E is below its own peaks, suggesting it is not excessively valued. The valuation implies the market expects steady, mid-single-digit earnings growth and successful pipeline execution to offset patent cliffs, but not explosive expansion.
JNJ is a good stock to buy for a specific investor profile: those seeking a defensive, low-volatility (beta 0.263) cornerstone holding with a reliable dividend. However, for investors seeking high growth or immediate capital appreciation, it is less compelling. The stock is fairly valued with a forward P/E of 17.84x, implying modest upside tied to earnings growth. The key risk is near-term revenue deceleration (9.08% YoY in Q4) and the decline of Stelara. It becomes a more compelling buy on a further pullback towards $215-$220, which would offer a better margin of safety.
JNJ is unequivocally suitable for long-term investment, with a suggested minimum holding period of 3-5 years. Its low beta (0.263), reliable dividend (payout ratio 46%), and business model built for durability make it a poor candidate for short-term trading, which is evidenced by its recent sharp underperformance versus the market over 1 and 3 months. Long-term investors benefit from compounding dividends, the company's ability to innovate over cycles, and the defensive stability it provides a portfolio. Short-term traders face headwinds from lack of volatility and near-term growth uncertainties that can lead to periods of stagnation, as currently observed.
